Evidence map›Paper›PMID 29409724›Full record

ArticleGlobal heart2018

Survival After MI in a Community Cohort Study: Contribution of Comorbidities in NSTEMI.

Randi E Foraker, Avirup Guha, Henry Chang, Emily C O'Brien, Julie K Bower, Elliott D Crouser, Wayne D Rosamond, Subha V Raman

Open access · hybridAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Global heart, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Randi E ForakerDivision of Cardiovascular Medicine, Ohio State University, Columbus, OH, USA; Division of Epidemiology, College of Public Health, Ohio State University, Columbus, OH, USA; Davis Heart and Lung Research Institute, Ohio State University, Columbus, OH, USA.
Avirup GuhaDivision of Cardiovascular Medicine, Ohio State University, Columbus, OH, USA.
Henry ChangDavis Heart and Lung Research Institute, Ohio State University, Columbus, OH, USA.
Emily C O'BrienDuke Clinical Research Institute, Durham, NC, USA.
Julie K BowerDivision of Epidemiology, College of Public Health, Ohio State University, Columbus, OH, USA.
Elliott D CrouserDivision of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Ohio State University, Columbus, OH, USA.
Wayne D RosamondDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Subha V RamanDivision of Cardiovascular Medicine, Ohio State University, Columbus, OH, USA; Davis Heart and Lung Research Institute, Ohio State University, Columbus, OH, USA. Electronic address: raman.1@osu.edu.
The Ohio State University · USClinical Research Institute · USLung Institute · USUniversity of North Carolina at Chapel Hill · US

Funding

Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular DystrophyR01HL116533 · NHLBI · OHIO STATE UNIVERSITY · PI RAFAEL-FORTNEY, JILL A, RAMAN, SUBHA V · 2013 to 2017
$2.7M
NHLBI NIH HHS HHSN268201000010CNHLBI NIH HHS HHSN268201000011CNHLBI NIH HHS HHSN268201000012CNHLBI NIH HHS R01 HL116533
6 · The paper itself

Abstract

backgroundNon-ST-segment elevation myocardial infarction (NSTEMI) comprises the majority of MI worldwide, yet mortality remains high. Management of NSTEMI is relatively delayed and heterogeneous compared with the "time is muscle" approach to ST-segment elevation MI, though it is unknown to what extent comorbid conditions drive NSTEMI mortality.

objectivesWe sought to quantify mortality due to MI versus comorbid conditions in patients with NSTEMI.

methodsParticipants of the ARIC (Atherosclerosis Risk in Communities) study cohort ages 45 to 64 years, who developed incident NSTEMI were identified and incidence-density matched to participants who did not experience an MI by age group, sex, race, and study community. We estimated hazard ratios for all-cause mortality, comparing those who developed NSTEMI to those who did not experience an MI.

resultsARIC participants with incident NSTEMI were more likely at baseline to be smokers, have diabetes and renal dysfunction, and take blood pressure or cholesterol-lowering medications than were participants who did not have an MI. Over one-half of participants experiencing NSTEMI died over a median follow-up of 8.4 years; incident NSTEMI was associated with 30% higher risk of mortality after adjusting for comorbid conditions (hazard ratio: 1.30; 95% confidence interval: 1.11 to 1.53).

conclusionsNSTEMI confers a significantly higher mortality hazard beyond what can be attributed to comorbid conditions. More consistent and effective strategies are needed to reduce mortality in NSTEMI amid comorbid conditions.

Indexed as

ComorbidityDiabetes MellitusFemaleFollow-Up StudiesHumansHypertensionIncidenceMaleMiddle AgedNon-ST Elevated Myocardial InfarctionPrevalenceResidence CharacteristicsRetrospective StudiesRisk FactorsSurvival RateTime Factors

Identifiers

PMID29409724
PMCPMC5963709
OpenAlexW2792806622

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.